AstraZeneca plc (LON:AZN)‘s stock had its “neutral” rating reiterated by J P Morgan Chase & Co in a report issued on Thursday. They presently have a GBX 4,500 ($58.12) price target on the biopharmaceutical company’s stock. J P Morgan Chase & Co’s price objective suggests a potential downside of 4.65% from the stock’s previous close.

A number of other research analysts have also weighed in on AZN. Shore Capital reissued a “hold” rating on shares of AstraZeneca plc in a research report on Wednesday, June 21st. Deutsche Bank AG dropped their price target on shares of AstraZeneca plc from GBX 5,700 ($73.61) to GBX 5,300 ($68.45) and set a “buy” rating on the stock in a research report on Thursday, August 3rd. HSBC Holdings plc set a GBX 4,100 ($52.95) price target on shares of AstraZeneca plc and gave the company a “sell” rating in a research report on Tuesday, August 8th. Liberum Capital reissued a “buy” rating and set a GBX 5,500 ($71.03) price target on shares of AstraZeneca plc in a research report on Monday, June 5th. Finally, Credit Suisse Group reissued a “neutral” rating and set a GBX 5,000 ($64.57) price target on shares of AstraZeneca plc in a research report on Monday, June 19th. Three analysts have rated the stock with a sell rating, ten have given a hold rating and nine have given a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of GBX 5,022.91 ($64.87).

Shares of AstraZeneca plc (LON:AZN) opened at 4719.50 on Thursday. The firm’s 50-day moving average is GBX 4,556.15 and its 200 day moving average is GBX 4,880.61. AstraZeneca plc has a 12 month low of GBX 3,996.00 and a 12 month high of GBX 5,520.00. The company’s market capitalization is GBX 59.75 billion.

COPYRIGHT VIOLATION NOTICE: This article was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another website, it was stolen and reposted in violation of international trademark and copyright laws. The correct version of this article can be accessed at https://www.thecerbatgem.com/2017/09/16/astrazeneca-plc-azn-stock-rating-reaffirmed-by-j-p-morgan-chase-co.html.

In other news, insider Nazneen Rahman acquired 39 shares of AstraZeneca plc stock in a transaction that occurred on Thursday, July 27th. The stock was bought at an average price of GBX 4,370 ($56.44) per share, with a total value of £1,704.30 ($2,201.08).

AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Stock Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related stocks with our FREE daily email newsletter.